Fig. 2
From: Nanotechnology for boosting ovarian cancer immunotherapy
(A) Adoptive immunotherapy using autologous young TILs and T-cells for ovarian cancer; (B) Combination of immunotherapy strategies (immune checkpoint blockade inhibitors and immunotherapeutic vaccines) with innovative targeted therapies (CAR-T cells, nanotechnology) to evade multidrug resistance in ovarian cancer